Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric crohn disease and a potential association with IL-23 receptor polymorphisms

Journal of Pediatric Gastroenterology and Nutrition

Volumn 56, Issue 5, 2013, Pages 512-518

  Sherlock, Mary E ^a   Walters, Thomas ^b   Tabbers, Merit M ^c   Frost, Karen ^b   Zachos, Mary ^a   Muise, Aleixo ^b   Pope, Elena ^b   Griffiths, Anne M ^b  

^a MCMASTER CHILDREN S HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Adverse events; Crohn disease; Infliximab; Psoriasis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; INTERLEUKIN 23 RECEPTOR; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; STEROID;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA DETERMINATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAINTENANCE THERAPY; MALE; MEDICAL RECORD REVIEW; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DEFECT; STEROID THERAPY; TOPICAL TREATMENT; TREATMENT DURATION;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CHILD; CROHN DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; POLYMORPHISM, GENETIC; PSORIASIS; RECEPTORS, INTERLEUKIN; SKIN; STEROIDS;

EID: 84877055533     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31828390ba     Document Type: Article

References (48)

1. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-To-severe Crohn's disease in children. Gastroenterology 2007;132:863-73
2. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007;13:424-30
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9
4. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52
5. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52: 582-91
6. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36
7. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-Type psoriasis: A randomised trial. Lancet 2001;357:1842-7
8. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64
9. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-To-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
10. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010;40:233-40
11. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat 2009;20:100-8
12. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-Alpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9:1-14
13. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-Tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010;8:1048-55
14. Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-Tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011;34:1318-27
15. Costa-Romero M, Coto-Segura P, Suarez-Saavedra S, et al. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm Bowel Dis 2008;14:1462-3
16. Avila Alvarez A, Garcia-Alonso L, Solar Boga A, et al. [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease]. An Pediatr (Barc) 2009;70:278-81
17. Pourciau C, Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol 2010;27:539-40
18. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-To-severe pediatric Crohn's disease. Am J Gastroenterol 2009;104:2566-71
19. Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011;52:230-2
20. Perman MJ, Lovell DJ, Denson LA, et al. Five cases of anti-Tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol 2012;29:454-9
21. Yates VM,Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 1982;106:323-30
22. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990;85:962-3
23. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009; 23:561-5
24. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003;48:805-21
25. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90
26. Duffin KC, Krueger GG. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol 2009;129:827-33
27. Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 2009;10:201-9
28. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-Analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-25
29. Franke A, Balschun T, Karlsen TH, et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008;40:713-5
30. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3
31. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008; 128:1653-61
32. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007;122:201-6
33. Einarsdottir E, Koskinen LL, Dukes E, et al. IL23R in the Swedish, Finnish, Hungarian and Italian populations: Association with IBD and psoriasis, and linkage to celiac disease. BMC Med Genet 2009;10:8
34. Imielinski M, Baldassano RN, Griffiths A, et al. Commonvariants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009;41:1335-40
35. Morris A, Rogers M, Fischer G, et al. Childhood psoriasis: A clinical review of 1262 cases. Pediatr Dermatol 2001;18:188-98
36. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010;162:633-6
37. Klein RQ, Spivack J, Choate KA. Psoriatic skin lesions induced by certolizumab pegol. Arch Dermatol 2010;146:1055-6
38. Mocciaro F, Renna S, Orlando A, et al. Severe cutaneous psoriasis after certolizumab pegol treatment: Report of a case. Am J Gastroenterol 2009;104:2867-8
39. Kupper TS. Immunologic targets in psoriasis. N Engl J Med 2003; 349:1987-90
40. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-Term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35
41. Fidder H, Schnitzler F, Ferrante M, et al. Long-Term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study. Gut 2009;58:501-8
42. Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-Alpha in psoriasiform eruptions associated with antitumour necrosis factor-Alpha treatments. Br J Dermatol 2009;161:1081-8
43. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor-Alpha antagonist therapy: A case series. J Rheumatol 2007;34:380-5
44. Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PloS One 2011;6:e17160
45. Cleynen I, Henckaerts L, Claes K, et al. Development of psoriasiform skin lesions under anti-TNF therapy: A common link with IL23R gene variants? Gastroenterology 2008;134:A461
46. Eriksen KW, Lovato P, Skov L, et al. Increased sensitivity to interferonalpha in psoriatic T cells. J Invest Dermatol 2005;125:936-44
47. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-Alpha production. J Exp Med 2005;202:135-43
48. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-Alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005; 102:3372-7